A Phase 1 Dose Escalation and Expansion Study of AK117

NCT04728334 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Akeso